Summit Therapeutics launches at-the-market equity program for up to $380 million

• Summit Therapeutics entered an at-the-market equity distribution agreement with J.P. Morgan Securities to sell up to $380 million of common stock.
• Sales can be made from time to time at prevailing market prices or negotiated prices, with the company retaining discretion over timing and size.
• J.P. Morgan will receive a commission of up to 3% of gross sales.
• The program uses the company’s effective Form S-3 registration statement filed June 9, 2026, with a prospectus supplement dated July 23, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Summit Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-314214), on July 23, 2026, and is solely responsible for the information contained therein.